Langley, R., Thaci, D., Blauvelt, A. , Tsai, T.-F., Miller, M. , Yu, J., Shen, Y.-K. , You, Y., Yang, Y.-W., Papp, K. , Puig, L. and Foley, P. 2022. Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 6, 2 (Mar. 2022), s1. DOI:https://doi.org/10.25251/skin.6.supp.1.